Malaria DNA vaccine - EntreMed

Drug Profile

Malaria DNA vaccine - EntreMed

Latest Information Update: 21 Dec 2004

Price : $50

At a glance

  • Originator National Institutes of Health (USA)
  • Developer EntreMed
  • Class Antimalarials; DNA vaccines; Gene therapies; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Malaria

Most Recent Events

  • 21 Dec 2004 Discontinued - Preclinical for Malaria in Panama (unspecified route)
  • 21 Dec 2004 Discontinued - Preclinical for Malaria in Peru (unspecified route)
  • 14 Nov 2002 Suspended - Preclinical for Malaria in Panama (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top